Evaluating the In Vivo Specificity of [
Animals
Brain
/ diagnostic imaging
Levetiracetam
/ administration & dosage
Magnetic Resonance Imaging
Male
Membrane Glycoproteins
/ metabolism
Models, Animal
Molecular Structure
Nerve Tissue Proteins
/ metabolism
Positron-Emission Tomography
Pyridines
/ chemistry
Pyrrolidinones
/ chemistry
Rats
Rats, Sprague-Dawley
Sensitivity and Specificity
PBIF
SV2A
SV2B
SV2C
[18F]UCB-H
blocking assay
distribution volume
epilepsy
microPET
preclinical imaging
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
01 May 2019
01 May 2019
Historique:
received:
22
03
2019
revised:
28
04
2019
accepted:
29
04
2019
entrez:
5
5
2019
pubmed:
6
5
2019
medline:
23
8
2019
Statut:
epublish
Résumé
The synaptic vesicle protein 2 (SV2) is involved in synaptic vesicle trafficking. The SV2A isoform is the most studied and its implication in epilepsy therapy led to the development of the first SV2A PET radiotracer [
Identifiants
pubmed: 31052478
pii: molecules24091705
doi: 10.3390/molecules24091705
pmc: PMC6538996
pii:
doi:
Substances chimiques
Membrane Glycoproteins
0
Nerve Tissue Proteins
0
Pyridines
0
Pyrrolidinones
0
SV2C protein, rat
0
Sv2a protein, rat
0
Sv2b protein, rat
0
UCB-H compound
0
Levetiracetam
44YRR34555
Types de publication
Comparative Study
Journal Article
Langues
eng
Références
Neuroscience. 1999;94(4):1279-90
pubmed: 10625067
J Cereb Blood Flow Metab. 2002 Aug;22(8):1019-34
pubmed: 12172388
Prostate. 2003 Apr 1;55(1):55-64
pubmed: 12640661
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6
pubmed: 15210974
J Clin Psychiatry. 2004 Sep;65(9):1162-3
pubmed: 15367040
J Neurosci. 2006 Jan 25;26(4):1303-13
pubmed: 16436618
Br J Pharmacol. 2008 Aug;154(8):1662-71
pubmed: 18500360
Epilepsia. 2009 Mar;50(3):422-33
pubmed: 18717715
Epilepsia. 2009 Jul;50(7):1729-40
pubmed: 19486357
J Cereb Blood Flow Metab. 1991 Mar;11(2):A38-44
pubmed: 1997486
Brain Res. 2011 Jan 7;1367:130-45
pubmed: 20869353
J Pharmacol Pharmacother. 2010 Jul;1(2):94-9
pubmed: 21350617
Neuroscience. 2012 Sep 27;221:12-20
pubmed: 22766234
Brain Res. 2013 Apr 24;1507:61-73
pubmed: 23458503
EJNMMI Res. 2013 May 07;3(1):35
pubmed: 23647774
BMC Neurosci. 2013 Aug 09;14:87
pubmed: 23937191
J Nucl Med. 2014 Aug;55(8):1336-41
pubmed: 24935992
ACS Med Chem Lett. 2014 Aug 19;5(10):1152-5
pubmed: 25313330
Mol Imaging Biol. 2015 Aug;17(4):557-64
pubmed: 25595813
J Cell Biol. 1985 Apr;100(4):1284-94
pubmed: 2579958
J Nucl Med. 2016 May;57(5):777-84
pubmed: 26848175
Pharmacogenomics. 2016 Apr;17(5):481-8
pubmed: 27019953
Nucl Med Biol. 2016 Jun;43(6):325-32
pubmed: 27260773
Sci Transl Med. 2016 Jul 20;8(348):348ra96
pubmed: 27440727
J Med Chem. 2016 Oct 13;59(19):8955-8966
pubmed: 27598384
Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2253-E2262
pubmed: 28246328
Front Mol Neurosci. 2017 May 22;10:148
pubmed: 28588450
Mol Pharm. 2017 Aug 7;14(8):2719-2725
pubmed: 28651055
J Nucl Med. 2018 Mar;59(3):380-381
pubmed: 29123011
Alzheimers Dement (N Y). 2017 Aug 30;3(4):481-486
pubmed: 29124105
Drug Discov Today Technol. 2017 Nov;25:45-52
pubmed: 29233267
Neurosci Lett. 2019 Jan 19;691:44-50
pubmed: 30075287
ACS Chem Neurosci. 2019 Mar 20;10(3):1544-1554
pubmed: 30396272
Mol Imaging Biol. 2018 Nov 20;:null
pubmed: 30460626
Mol Cell Neurosci. 2019 Feb 20;:null
pubmed: 30796959
Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2150-4
pubmed: 7681585
J Neurosci. 1994 Sep;14(9):5223-35
pubmed: 8083732